CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
EN
Home / Corvus Pharmaceuticals, INC. (CRVS) / soquelitinib
Forward catalyst · CRVS

soquelitinib

Sponsor Corvus Pharmaceuticals, INC. · listed as CRVS

READOUT Phase 3 Confidence: medium Source: clinicaltrials

soquelitinib is a clinical-stage drug asset sponsored by Corvus Pharmaceuticals, INC., listed as CRVS. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Nov 2027 (month precision, medium confidence), tied to trial NCT06561048. The asset is in Phase 3 and currently recruiting, studied in Peripheral T-Cell Lymphoma, Not Otherwise Specified.

Next catalyst

Event typeREADOUT
Expected date2027-11-30
As disclosedNov 2027
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06561048
PhasePHASE3
StatusRECRUITING
Lead sponsorCorvus Pharmaceuticals, Inc.
Listed asCRVS
Condition(s)Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Follicular T-Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH P…
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.

Get the full dataset — $499 →   More CRVS catalysts

Related catalysts and sponsor